Christie, Jason D <br/><br/>
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.  [electronic resource] 

 -  Critical care medicine  Sep 2015 
 - 1859-69 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1530-0293 
<br/><br/><label>Standard No.: </label>10.1097/CCM.0000000000001132  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>C-Reactive Protein--drug effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Hospital Mortality<br/>Humans<br/>Inflammation Mediators--metabolism<br/>Interleukin-6--biosynthesis<br/>Interleukin-8--drug effects<br/>Male<br/>Middle Aged<br/>Pyridones--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Receptors, Tumor Necrosis Factor, Type I--drug effects<br/>Respiratory Distress Syndrome--prevention & control<br/>Trauma Severity Indices<br/>Wounds and Injuries--drug therapy<br/>p38 Mitogen-Activated Protein Kinases--antagonists & inhibitors